RhumbLine Advisers
ABUS icon

RhumbLine Advisers’s Arbutus Biopharma ABUS Stock Holding History

RhumbLine Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$892K Sell
186,564
-2,859
-2% -$13.8K ﹤0.01% 2343
2026
Q2 		$909K Buy
189,423
+10,638
+6% +$46.7K ﹤0.01% 2374
2026
Q1 		$805K Sell
178,785
-4,465
-2% -$19.5K ﹤0.01% 2311
2025
Q4 		$881K Sell
183,250
-28,534
-13% -$128K ﹤0.01% 2305
2025
Q3 		$961K Buy
211,784
+3,979
+2% +$14.6K ﹤0.01% 2268
2025
Q2 		$642K Buy
207,805
+7,048
+4% +$23.4K ﹤0.01% 2513
2025
Q1 		$701K Buy
200,757
+12,159
+6% +$40.5K ﹤0.01% 2351
2024
Q4 		$617K Buy
188,598
+10,724
+6% +$39.4K ﹤0.01% 2532
2024
Q3 		$685K Sell
177,874
-7,193
-4% -$27.6K ﹤0.01% 2497
2024
Q2 		$572K Buy
185,067
+14,607
+9% +$43.8K ﹤0.01% 2574
2024
Q1 		$440K Buy
170,460
+5,836
+4% +$15.1K ﹤0.01% 2744
2023
Q4 		$412K Sell
164,624
-3,608
-2% -$7.07K ﹤0.01% 2780
2023
Q3 		$342K Buy
168,232
+2,415
+1% +$5.06K ﹤0.01% 2856
2023
Q2 		$381K Buy
165,817
+6,690
+4% +$17.4K ﹤0.01% 2864
2023
Q1 		$482K Buy
159,127
+9,592
+6% +$27.1K ﹤0.01% 2449
2022
Q4 		$348K Buy
149,535
+6,695
+5% +$16K ﹤0.01% 2614
2022
Q3 		$273K Buy
142,840
+7,916
+6% +$18.6K ﹤0.01% 2755
2022
Q2 		$366K Buy
134,924
+31,146
+30% +$79.7K ﹤0.01% 2648
2022
Q1 		$309K Buy
103,778
+13,243
+15% +$40.5K ﹤0.01% 2637
2021
Q4 		$352K Buy
90,535
+71
+0.1% +$276 ﹤0.01% 2652
2021
Q3 		$388K Buy
90,464
+2,546
+3% +$8.48K ﹤0.01% 2665
2021
Q2 		$266K Buy
+87,918
New +$272K ﹤0.01% 2830
2019
Q2 		– Sell
-48,597
Closed -$174K – 2967
2019
Q1 		$174K Sell
48,597
-435
-0.9% -$1.67K ﹤0.01% 2776
2018
Q4 		$188K Buy
49,032
+15,416
+46% +$75.9K ﹤0.01% 2754
2018
Q3 		$318K Buy
33,616
+260
+0.8% +$2.58K ﹤0.01% 2487
2018
Q2 		$243K Buy
+33,356
New +$199K ﹤0.01% 2640

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

RhumbLine Advisers's ABUS Position: Q3 2026 in Review

RhumbLine Advisers reduced its Arbutus Biopharma (ABUS) stake by 1.5% in Q3 2026, selling an estimated $13.8K and leaving 186,564 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

RhumbLine Advisers first reported a position in ABUS in Q2 2018 and has held it in 26 quarters since. The position peaked at $961K in Q3 2025. 150 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • RhumbLine Advisers held 186,564 shares of Arbutus Biopharma worth $892K as of Q3 2026.
  • RhumbLine Advisers sold 2,859 Arbutus Biopharma shares in Q3 2026, an estimated $13.8K.
  • Arbutus Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2343 holding.
  • RhumbLine Advisers first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 26 quarters since.
  • RhumbLine Advisers's Arbutus Biopharma position peaked at $961K in Q3 2025.
  • 150 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.